599 related articles for article (PubMed ID: 29345728)
1. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.
Nikiforova MN; Mercurio S; Wald AI; Barbi de Moura M; Callenberg K; Santana-Santos L; Gooding WE; Yip L; Ferris RL; Nikiforov YE
Cancer; 2018 Apr; 124(8):1682-1690. PubMed ID: 29345728
[TBL] [Abstract][Full Text] [Related]
2. Thyroid cytology smear slides: An untapped resource for ThyroSeq testing.
Nikiforova MN; Lepe M; Tolino LA; Miller ME; Ohori NP; Wald AI; Landau MS; Kaya C; Malapelle U; Bellevicine C; Troncone G; Nikiforov YE; Baloch Z
Cancer Cytopathol; 2021 Jan; 129(1):33-42. PubMed ID: 32697051
[TBL] [Abstract][Full Text] [Related]
3. Benign call rate and molecular test result distribution of ThyroSeq v3.
Ohori NP; Landau MS; Carty SE; Yip L; LeBeau SO; Manroa P; Seethala RR; Schoedel KE; Nikiforova MN; Nikiforov YE
Cancer Cytopathol; 2019 Mar; 127(3):161-168. PubMed ID: 30561907
[TBL] [Abstract][Full Text] [Related]
4. Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology.
Nikiforov YE; Carty SE; Chiosea SI; Coyne C; Duvvuri U; Ferris RL; Gooding WE; LeBeau SO; Ohori NP; Seethala RR; Tublin ME; Yip L; Nikiforova MN
Thyroid; 2015 Nov; 25(11):1217-23. PubMed ID: 26356635
[TBL] [Abstract][Full Text] [Related]
5. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
Steward DL; Carty SE; Sippel RS; Yang SP; Sosa JA; Sipos JA; Figge JJ; Mandel S; Haugen BR; Burman KD; Baloch ZW; Lloyd RV; Seethala RR; Gooding WE; Chiosea SI; Gomes-Lima C; Ferris RL; Folek JM; Khawaja RA; Kundra P; Loh KS; Marshall CB; Mayson S; McCoy KL; Nga ME; Ngiam KY; Nikiforova MN; Poehls JL; Ringel MD; Yang H; Yip L; Nikiforov YE
JAMA Oncol; 2019 Feb; 5(2):204-212. PubMed ID: 30419129
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis.
Borowczyk M; Szczepanek-Parulska E; Olejarz M; Więckowska B; Verburg FA; Dębicki S; Budny B; Janicka-Jedyńska M; Ziemnicka K; Ruchała M
Endocr Pathol; 2019 Mar; 30(1):8-15. PubMed ID: 30591992
[TBL] [Abstract][Full Text] [Related]
7. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay.
Nikiforov YE; Carty SE; Chiosea SI; Coyne C; Duvvuri U; Ferris RL; Gooding WE; Hodak SP; LeBeau SO; Ohori NP; Seethala RR; Tublin ME; Yip L; Nikiforova MN
Cancer; 2014 Dec; 120(23):3627-34. PubMed ID: 25209362
[TBL] [Abstract][Full Text] [Related]
8. The role of ThyroSeq V3 testing in the management of patients with indeterminate thyroid nodules on fine needle aspiration.
Selvaggi SM
Diagn Cytopathol; 2021 Jul; 49(7):838-841. PubMed ID: 33864719
[TBL] [Abstract][Full Text] [Related]
9. Molecular Profiling of 50 734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management.
Chiosea S; Hodak SP; Yip L; Abraham D; Baldwin C; Baloch Z; Gulec SA; Hannoush ZC; Haugen BR; Joseph L; Kargi AY; Khanafshar E; Livhits MJ; McIver B; Patel K; Patel SG; Randolph GW; Shaha AR; Sharma J; Stathatos N; van Zante A; Carty SE; Nikiforov YE; Nikiforova MN
J Clin Endocrinol Metab; 2023 Oct; 108(11):2999-3008. PubMed ID: 37071871
[TBL] [Abstract][Full Text] [Related]
10. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
Gortakowski M; Feghali K; Osakwe I
Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
[No Abstract] [Full Text] [Related]
11. The diagnostic application of RNA sequencing in patients with thyroid cancer: an analysis of 851 variants and 133 fusions in 524 genes.
Pagan M; Kloos RT; Lin CF; Travers KJ; Matsuzaki H; Tom EY; Kim SY; Wong MG; Stewart AC; Huang J; Walsh PS; Monroe RJ; Kennedy GC
BMC Bioinformatics; 2016 Jan; 17 Suppl 1(Suppl 1):6. PubMed ID: 26818556
[TBL] [Abstract][Full Text] [Related]
12. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
Jug RC; Datto MB; Jiang XS
Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
[TBL] [Abstract][Full Text] [Related]
13. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.
Nikiforova MN; Wald AI; Roy S; Durso MB; Nikiforov YE
J Clin Endocrinol Metab; 2013 Nov; 98(11):E1852-60. PubMed ID: 23979959
[TBL] [Abstract][Full Text] [Related]
14. Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules.
Yang SP; Nga ME; Bundele MM; Chiosea SI; Tan SH; Lum JHY; Parameswaran R; Lim MY; Li H; Cheah WK; Sek KS; Tan ATH; Loh TKS; Ngiam KY; Tan WB; Huang X; Ho TWT; Lim KH; Lim CM; Singaporewalla RM; Rao AD; Rao NCL; Chua DYK; Chin DC; Wald AI; LiVolsi VA; Nikiforov YE; Tai ES
Cancer Cytopathol; 2024 May; 132(5):309-319. PubMed ID: 38319805
[TBL] [Abstract][Full Text] [Related]
15. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules.
Beaudenon-Huibregtse S; Alexander EK; Guttler RB; Hershman JM; Babu V; Blevins TC; Moore P; Andruss B; Labourier E
Thyroid; 2014 Oct; 24(10):1479-87. PubMed ID: 24811481
[TBL] [Abstract][Full Text] [Related]
16. Centrifuged supernatants from FNA provide a liquid biopsy option for clinical next-generation sequencing of thyroid nodules.
Ye W; Hannigan B; Zalles S; Mehrotra M; Barkoh BA; Williams MD; Cabanillas ME; Edeiken-Monroe B; Hu P; Duose D; Wistuba II; Medeiros LJ; Stewart J; Luthra R; Roy-Chowdhuri S
Cancer Cytopathol; 2019 Mar; 127(3):146-160. PubMed ID: 30620446
[TBL] [Abstract][Full Text] [Related]
17. Distinguishing parathyroid and thyroid lesions on ultrasound-guided fine-needle aspiration: A correlation of clinical data, ancillary studies, and molecular analysis.
Cho M; Oweity T; Brandler TC; Fried K; Levine P
Cancer Cytopathol; 2017 Sep; 125(9):674-682. PubMed ID: 28621914
[TBL] [Abstract][Full Text] [Related]
18. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
19. Preoperative detection of malignancy in fine-needle aspiration cytology (FNAC) smears with indeterminate cytology (Bethesda III, IV) by a combined molecular classifier.
Titov S; Demenkov PS; Lukyanov SA; Sergiyko SV; Katanyan GA; Veryaskina YA; Ivanov MK
J Clin Pathol; 2020 Nov; 73(11):722-727. PubMed ID: 32213552
[TBL] [Abstract][Full Text] [Related]
20. Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodules.
Marcadis AR; Valderrabano P; Ho AS; Tepe J; Swartzwelder CE; Byrd S; Sacks WL; Untch BR; Shaha AR; Xu B; Lin O; Ghossein RA; Wong RJ; Marti JL; Morris LGT
Surgery; 2019 Jan; 165(1):17-24. PubMed ID: 30360906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
